Roberto Iacone, Alentis CEO

Swiss-based up­start march­es to­ward the clin­ic with a unique ap­proach to fi­bro­sis treat­ment

For more than 10 years, Thomas Baumert has been care­ful­ly study­ing a pro­tein called Claudin-1 (CLDN1) for its role in fi­bro­sis. Now, hot off a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.